← Back to all trials
Not Yet Recruiting
NCT05672082
Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma, a Pilot Study
Conditions: Glioma
Sex: All
Ages: 18 Years – N/A
Phase: NA
Enrollment: 20
Sponsor: Center Eugene Marquis
Summary
The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain.
However, there is an increase in the expression of TSPO in glial tumors.
It is even associated with a higher malignancy and a shorter survival of patients.
Among the different TSPO ligands, the most commonly used tracers in PET imaging are [18F]DPA-714 and 18F-GE180.
We hypothesize that [18F]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.
Eligibility Criteria
Inclusion Criteria:Age greater than or equal to 18 yearsSuspicion of an operable diffuse gliomaWritten informed consent (signed)Affiliated or beneficiary of a social security planExclusion Criteria:Suspicion of grade I gliomaSurgical urgency (less than 8 days between the suspected diagnosis and surgery)Pregnant or breastfeeding womanPersons deprived of liberty or under guardianshipImpossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons
Source: ClinicalTrials.gov (NCT05672082). StuddyBuddy aggregates publicly available trial information.